Appian International Research Enters Second Year with Ongoing Trials in Seven Countries

CHARLOTTE, NC, June 29, 2007-This week, Appian International Research, Inc. announced plans to expand its generic pharmaceuticals development services as the company enters its second year.

“Appian International Research as a company is still relatively new to the industry, but our team certainly isn’t,” explained Appian’s President, Dr. Grier Harris.

“Appian International Research is the outgrowth of Appian Services, a consulting firm that we established in 2003 to provide contract development services to generic and small Pharma companies. We help our clients manage strategic development plans, designed study protocols, compiled reports, and performed site audits, whatever it took to help them overcome the hurdles inherent in pharmaceutical product development. As business grew, we decided to focus on our expanding network of international resources and broaden our range of services.”

“Our specialty, of course, is the design and management of clinical endpoint bioequivalence trials, the sort of trials that the FDA’s Office of Generic Drugs requires for the approval of topically active drugs. Most of our early work has been in dermatological products, but we are currently expanding into some other therapeutic areas that will take advantage of the many years of experience that we have in topical drug development.”